Business Wire

CA-NEXON-AMERICA

17.3.2021 16:02:05 CET | Business Wire | Press release

Share
Waddle Into War With The New Maestro Class In V4 Global Update

The Maestro, a brilliant tactician wielding both a sword and a pistol, joins Nexon’s MMORPG cross-platform marvel V4 today as its third new class along with new gear and various limited-time reward events, including one special for Amazon Prime members.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005156/en/

A melody crafted through blade and gun, the Maestro is the third class to join V4 since launch. The Maestro uses an enchanted sword and pistol to dole out ranged damage, leading the battle with a variety of brilliant techniques. Equipped with the Rapier main weapon and Magishot sub weapon, he can further shake up combat by switching between Indignant and Composed stances to play the battlefield like a fiddle, letting loose with furious strength or lining up precision attacks against the mightiest foes.

The Maestro Update also introduces two new types of gear, Runes and Crests.

  • Runes are a versatile gear type that improves defense stats by giving between 1 and up to a maximum of 5 traits when enhanced, starting at +6 enhancement. Runes are available from the V4 shop.
  • Crests are supplemental gear that improve a character’s attack through Crit Hit stats. Rare and better crests provide greater strength by also including defense, PVP, and additional Crit DMG stats. Crests can be found in the Arrogant Plains, Despaired Forest, and Land of Evenfall warzones as well as Lunatra battlefields, which require more than 50,000 CP to enter.
  • Both Rune and Crest Enhance Scrolls are required and guarantee up to +2 enhancement, while attempting +3 or higher enhancements may destroy the gear.

To celebrate the arrival of the Maestro, V4 Global players can partake in limited-time reward events including:

  • Costume Giveaway Event: All players who log in after the Maestro update, starting March 17, can redeem a free Rare Costume. The “Valiant King” or “Judgement Queen” costumes will be available on the in-game event page, based on the player’s chosen class.
  • Red Gem Festival Event: The Red Gem Festival will reward players based on the number of Red Gems they have spent since the V4 Global launch, from July 23, 2020 through March 28, 2021. Using the in-game event page, players who have spent more than 300 gems across all characters will receive rewards according to available exchange tables; players who have spent 299 gems or less will also receive a small reward.
  • Amazon Prime Reward Cycles: Starting today, V4 Global players on mobile devices will be able to link their Amazon Prime Account through the in-game menu to receive exclusive rewards once each cycle. Players must link their Amazon Prime accounts during each cycle to receive that cycle’s unique rewards, and the rewards include the Super Starter Pack (containing a 30-day subscription, a Beginner Gear Pack, and a Beginner Accessory Pack) and Rare mounts.

For more information about the all-new V4 Maestro class update, please visit https://www.nexon.com/v4/ or follow @V4Global on Twitter for the latest updates.

Press Assets:

Social: Facebook / Twitter / Instagram / Discord / YouTube

About V4 https://www.nexon.com/v4

Powered by Unreal Engine 4, V4 is a cross-platform free-to-play fantasy MMORPG that gives players the ability to customize their heroes as they defend a breathtaking world from the forces of darkness. With exquisitely detailed battles and offense-focused classes, players can team up with warriors from all over the world on mobile and PC to defeat evil.

About Nexon America Inc. https://www.nexon.com

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

Social Media:

https://www.facebook.com/V4Global

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye